Asthma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for asthma. 147 active patents protecting 9 drugs from 7+ originators. First major cliff: 2027. Daily refresh.

9
Approved drugs
147
Active US patents
65/100
Avg vulnerability
$11.2B
Annual revenue covered

Originators in Asthma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Haleon Us Holdings 41 patents AstraZeneca K.K. 37 patents Generic (originally Schering) 33 patents Merck & Co. 22 patents Boehringer Ingelheim 9 patents Covis 4 patents Padagis Us 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating asthma. Each bar = one year. Y-axis scaled to peak year (31 patents).

9
26
18
27
12
28
9
29
31
30
13
31
6
32
4
33
23
34
5
36
3
37
3
38
4
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Arnuity Ellipta
FLUTICASONE FUROATE
 Haleon Us Holdings 41 61 $3.1B 2027-06-14
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Spiriva
TIOTROPIUM BROMIDE
 Boehringer Ingelheim 9 68 $2.5B 2026-07-19
Omnaris
CICLESONIDE
 Covis 4 80 — 2028-02-01
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9119863 Pulmicort Respules method of use 93 2026-11-09
8497258 Pulmicort Respules method of use 93 2026-11-09
8975243 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8511304 Arnuity Ellipta method of use 83 2027-06-14
11116721 Arnuity Ellipta method of use 83 2029-02-26
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
8022082 Spiriva other 80 2026-07-19
7396341 Spiriva other 80 2027-04-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10406332 Elocon formulation 25 2034-03-13
10799642 Decadron formulation 31 2032-05-11
8763222 Elocon formulation 31 2032-02-08
8409606 Decadron formulation 31 2030-05-14
11679210 Elocon formulation 33 2038-09-03

Related